Literature DB >> 18160222

Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization.

C M Butler1, A M Nijhof, J H van der Kolk, O B de Haseth, A Taoufik, F Jongejan, D J Houwers.   

Abstract

Imidocarb treatment of horses infected with Babesia caballi is supposed to eliminate the infection, but data on the efficacy of this treatment is scarce. The study presented here concerns four Paso Fino horses, which were imported into the island of Curacao on the basis of a piroplasmosis negative complement fixation test (CFT). Upon re-testing with an indirect fluorescent antibody test immediately after arrival in Curacao, two horses appeared to have antibodies to B. caballi and all horses had antibodies to Theileria equi. Subsequent testing with polymerase chain reaction combined with a reverse line blot yielded positive results for both agents in all four horses. Treatment with five consecutive doses of imidocarb dipropionate (4.7 mg/kg BW im q 72 h), temporarily resulted in negative results, but B. caballi and T. equi were detected again in the samples taken at 6 and 18 weeks after completion of the treatment. These results confirm that the CFT is not a suitable test for pre-import testing and that even high dose treatment with imidocarb may not be capable of eliminating B. caballi and T. equi infections from healthy carriers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160222     DOI: 10.1016/j.vetpar.2007.11.010

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  7 in total

Review 1.  Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.

Authors:  Wesley C Van Voorhis; J Stone Doggett; Marilyn Parsons; Matthew A Hulverson; Ryan Choi; Samuel L M Arnold; Michael W Riggs; Andrew Hemphill; Daniel K Howe; Robert H Mealey; Audrey O T Lau; Ethan A Merritt; Dustin J Maly; Erkang Fan; Kayode K Ojo
Journal:  Exp Parasitol       Date:  2017-01-05       Impact factor: 2.011

2.  Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential.

Authors:  O Nicolas Schwint; Massaro W Ueti; Guy H Palmer; Lowell S Kappmeyer; Melissa T Hines; R Timothy Cordes; Donald P Knowles; Glen A Scoles
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

3.  Re-emergence of the apicomplexan Theileria equi in the United States: elimination of persistent infection and transmission risk.

Authors:  Massaro W Ueti; Robert H Mealey; Lowell S Kappmeyer; Stephen N White; Nancy Kumpula-McWhirter; Angela M Pelzel; Juanita F Grause; Thomas O Bunn; Andy Schwartz; Josie L Traub-Dargatz; Amy Hendrickson; Benjamin Espy; Alan J Guthrie; W Kent Fowler; Donald P Knowles
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

Review 4.  Current advances in detection and treatment of babesiosis.

Authors:  J Mosqueda; A Olvera-Ramirez; G Aguilar-Tipacamu; G J Canto
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 5.  A review of Theileria diagnostics and epidemiology.

Authors:  Ben J Mans; Ronel Pienaar; Abdalla A Latif
Journal:  Int J Parasitol Parasites Wildl       Date:  2015-01-06       Impact factor: 2.674

6.  Lactate Dehydrogenase as a Potential Therapeutic Drug Target to Control Babesia bigemina.

Authors:  Lan He; Reginaldo G Bastos; Long Yu; Jacob M Laughery; Carlos E Suarez
Journal:  Front Cell Infect Microbiol       Date:  2022-04-19       Impact factor: 6.073

Review 7.  Twenty Years of Equine Piroplasmosis Research: Global Distribution, Molecular Diagnosis, and Phylogeny.

Authors:  Sharon Tirosh-Levy; Yuval Gottlieb; Lindsay M Fry; Donald P Knowles; Amir Steinman
Journal:  Pathogens       Date:  2020-11-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.